Kenvue stock has struggled this year, but an acquisition offer is giving investors hope leading up to this week's earnings ...

Kimberly-Clark plans to acquire Kenvue in a $48.7 billion deal, aiming to boost long-term growth and synergies. Learn more ...

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

The consumer health and wellness giants are both Dividend Kings, with more than 50 years of consecutive annual payout ...

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Under the agreement, each Kenvue Inc. (NYSE:KVUE) shareholder would receive $3.5 per share in cash as well as 0.14625 ...

Kimberly-Clark (NASDAQ:KMB) is making a massive bet but investors aren't sure on how to feel about it. The maker of Kleenex ...

The Kimberly-Clark/Kenvue transaction is one of the worst-received major merger deals in recent years. Investors wondered why ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.

With the merger, Kimberley-Clark would surpass Unilever to become the second-largest company that sells health and wellness products, after Procter & Gamble Co.

Kimberly-Clark announces the acquisition of Kenvue, the maker of Tylenol, in a landmark $48.7 billion deal to create a ...

A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue ...